A pilot study of vinorelbine safety and pharmacokinetics in patients with varying degrees of liver dysfunction

A pilot study of vinorelbine safety and pharmacokinetics in patients with varying degrees of liver dysfunction is organized by Society for Translational Oncology (STO).

Release Date: 09/24/2019
Expiry Date: 09/24/2021

Accreditation:
The Society for Translational Oncology designates this journal-based CME activity for a maximum of 1.00 AMA PRA Category 1 Credit™.

Learning objectives:
• Correlate the effect of degree of hepatie impairment on vinorelbine pharmocokinetic parameters.
• Evaluate data regarding adverse effects associated with vinorelbine in patients with cancer who have varying degrees of hepatic impairment.

Additional details will be posted as soon as information is available.